Morrow et al16 reported that nearly one-fourth of women who refused to undergo reconstruction after mastectomy because they feared about its potential interference with detection of recurrence despite the clinical evidence not supporting this contention.26 Furthermore, HER2-overexpressing and triple negative breast cancers are more likely to receive neoadjuvant chemotherapy because of their superiorities in systemic treatment response.27,28 Side effects or complications related to neoadjuvant chemotherapy certainly could impact decisions on immediate postmastectomy reconstruction. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.